{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:15:38Z","timestamp":1779282938978,"version":"3.51.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41380-026-03470-1","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:40:22Z","timestamp":1770403222000},"page":"3407-3415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuropsychiatric drug development in China: Current status and emerging trends"],"prefix":"10.1038","volume":"31","author":[{"given":"Jingyao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1540-4385","authenticated-orcid":false,"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"3470_CR1","doi-asserted-by":"publisher","unstructured":"Study on the National Conditions of Modernization with Chinese Characteristics. Available from: https:\/\/doi.org\/10.1007\/978-981-97-7447-0.","DOI":"10.1007\/978-981-97-7447-0"},{"key":"3470_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107488","volume":"210","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhao G, Jia LL, Li C, Wang X, Jing C, et al. Trends of drug licensing in China: From bring-in to go-global. Pharmacol Res. 2024;210:107488.","journal-title":"Pharmacol Res"},{"key":"3470_CR3","doi-asserted-by":"publisher","first-page":"e2337348","DOI":"10.1001\/jamanetworkopen.2023.37348","volume":"6","author":"XX Luo","year":"2023","unstructured":"Luo XX, Du X, Li ZQ, Liu JW, Lv XF, Li HR, et al. Clinical benefit, price, and uptake for cancer biosimilars vs reference drugs in China. JAMA Netw Open. 2023;6:e2337348.","journal-title":"JAMA Netw Open"},{"key":"3470_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41420-021-00697-5","volume":"7","author":"M Liao","year":"2021","unstructured":"Liao M, Dong QY, Chen RQ, Xu LQ, Jiang YX, Guo ZX, et al. Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis. Cell Death Discov. 2021;7:297.","journal-title":"Cell Death Discov"},{"key":"3470_CR5","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Novel Drugs. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda."},{"key":"3470_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/d41573-024-00034-2","volume":"23","author":"XC Zhi","year":"2024","unstructured":"Zhi XC, Li Q, Shao LM. Approvals by the China NMPA in 2023. Nat Rev Drug Discov. 2024;23:164\u20135.","journal-title":"Nat Rev Drug Discov"},{"key":"3470_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","volume":"9","author":"L Zheng","year":"2024","unstructured":"Zheng L, Wang WJ, Sun Q. Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA. Signal Transduct Target Ther. 2024;9:46.","journal-title":"Signal Transduct Target Ther"},{"key":"3470_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41588-020-0596-3","volume":"52","author":"MB Fernando","year":"2020","unstructured":"Fernando MB, Ahfeldt T, Brennand KJ. Modeling the complex genetic architectures of brain disease. Nat Genet. 2020;52:363\u20139.","journal-title":"Nat Genet"},{"key":"3470_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.apsb.2022.01.011","volume":"12","author":"CT Lewandowskia","year":"2022","unstructured":"Lewandowskia CT, Lahamb MS, Thatcherb GRJ. Remembering your A, B, C\u2019s: Alzheimer\u2019s disease and ABCA1. Acta Pharm Sin B. 2022;12:995\u20131018.","journal-title":"Acta Pharm Sin B"},{"key":"3470_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","volume":"21","author":"F Vincent","year":"2022","unstructured":"Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. 2022;21:899\u2013914.","journal-title":"Nat Rev Drug Discov"},{"key":"3470_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-023-01536-y","volume":"21","author":"BS Park","year":"2023","unstructured":"Park BS, Jeon HJ, Chi SG, Kim T. Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA. BMC Biol. 2023;21:45.","journal-title":"BMC Biol"},{"key":"3470_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-025-01075-4","volume":"20","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Yu LL, Bi CH, Huang LP, Su BD, Nie JX, et al. A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chin Med. 2025;20:40.","journal-title":"Chin Med"},{"key":"3470_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","volume":"9","author":"R Morphy","year":"2004","unstructured":"Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9:641\u201351.","journal-title":"Drug Discov Today"},{"key":"3470_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507764","volume":"12","author":"AQ Lin","year":"2025","unstructured":"Lin AQ, Che C, Jiang AM, Qi C, Glaviano A, Zhao ZJ, et al. Protein spatial structure meets artificial intelligence: Revolutionizing drug synergy\u2013antagonism in precision medicine. Adv Sci (Weinh). 2025;12:e07764.","journal-title":"Adv Sci (Weinh)"},{"key":"3470_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1001\/jama.2020.26867","volume":"325","author":"SJ Mendelson","year":"2021","unstructured":"Mendelson SJ, Prabhakaran S. Diagnosis and management of transient ischemic attack and acute ischemic stroke. JAMA. 2021;325:1088\u201398.","journal-title":"JAMA"},{"issue":"20 Suppl 2","key":"3470_CR16","first-page":"S6","volume":"97","author":"V Saini","year":"2021","unstructured":"Saini V, Guada L, Yavagal DR. Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology. 2021;97(20 Suppl 2):S6\u2013S16.","journal-title":"Neurology"},{"key":"3470_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.822342","volume":"12","author":"N Chen","year":"2022","unstructured":"Chen N, Wu XT, Zhou MK, Yang RD, Chen DF, Liao M, et al. Telestroke for the treatment of ischemic stroke in Western China during the COVID-19 pandemic: A multicenter observational study. Front Neurol. 2022;12:822342.","journal-title":"Front Neurol"},{"key":"3470_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000525822","volume":"85","author":"MG Mosconi","year":"2022","unstructured":"Mosconi MG, Paciaroni M. Treatments in ischemic stroke: Current and future. Eur Neurol. 2022;85:349\u201366.","journal-title":"Eur Neurol"},{"key":"3470_CR19","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","volume":"45","author":"JF Meschia","year":"2014","unstructured":"Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;45:3754\u2013832.","journal-title":"Stroke"},{"key":"3470_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-021-00605-6","volume":"18","author":"M Fisher","year":"2022","unstructured":"Fisher M, Savitz SI. Pharmacological brain cytoprotection in acute ischaemic stroke - renewed hope in the reperfusion era. Nat Rev Neurol. 2022;18:193\u2013202.","journal-title":"Nat Rev Neurol"},{"key":"3470_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bph.14102","volume":"175","author":"GX Zhang","year":"2017","unstructured":"Zhang GX, Zhang T, Li N, Wu LM, Gu JB, Li CM, et al. Tetramethylpyrazine nitrone activates the BDNF\/Akt\/CREB pathway to promote post\u2010ischaemic neuroregeneration and recovery of neurological functions in rats. Br J Pharmacol. 2017;175:517\u201331.","journal-title":"Br J Pharmacol"},{"key":"3470_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12017-018-8478-x","volume":"20","author":"GX Zhang","year":"2018","unstructured":"Zhang GX, Zhang T, Wu LM, Zhou XH, Gu JB, Li CM, et al. Neuroprotective Effect and Mechanism of Action of Tetramethylpyrazine Nitrone for Ischemic Stroke Therapy. Neuromolecular Med. 2018;20:97\u2013111.","journal-title":"Neuromolecular Med"},{"key":"3470_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/srep37148","volume":"6","author":"ZJ Zhang","year":"2016","unstructured":"Zhang ZJ, Zhang GX, Sun YW, Szeto SSW, Law HCH, Quan Q, et al. Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy. Sci Rep. 2016;6:37148.","journal-title":"Sci Rep"},{"key":"3470_CR24","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.7150\/thno.58364","volume":"11","author":"J Li","year":"2021","unstructured":"Li J, Zhang L, Xu C, Shen YY, Lin YH, Zhang Y, et al. A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and \u03b12-containning GABAARs. Theranostics. 2021;11:5970\u201385.","journal-title":"Theranostics"},{"key":"3470_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/svn-2022-002156","volume":"8","author":"HY Wu","year":"2023","unstructured":"Wu HY, Huang ZQ, Wang X, Chen MY, Chen W, Hua Y, et al. Preclinical evaluation of ZL006-05, a new antistroke drug with fast-onset antidepressant and anxiolytic effects. Stroke Vasc Neurol. 2023;8:463\u201374.","journal-title":"Stroke Vasc Neurol"},{"key":"3470_CR26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41401-020-00547-7","volume":"42","author":"YD Zheng","year":"2020","unstructured":"Zheng YD, Zhang H, Zhan Y, Bian YC, Ma S, Gan HX, et al. Pharmacokinetics, mass balance, and metabolism of [14C] vicagrel, a novel irreversible P2Y12 inhibitor in humans. Acta Pharmacol Sin. 2020;42:1535\u201346.","journal-title":"Acta Pharmacol Sin"},{"key":"3470_CR27","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1021\/jm300038c","volume":"55","author":"JQ Shan","year":"2012","unstructured":"Shan JQ, Zhang BY, Zhu YQ, Jiao B, Zheng WY, Qi XW, et al. Overcoming Clopidogrel Resistance: Discovery of Vicagrel as a Highly Potent and Orally Bioavailable Antiplatelet Agent. J Med Chem. 2012;55:3342\u201352.","journal-title":"J Med Chem"},{"key":"3470_CR28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1124\/dmd.124.001739","volume":"52","author":"C Yang","year":"2024","unstructured":"Yang C, Gong JR, Xue MZ, Huang WS, Yuan YL, Chen C, et al. Effects of the Thiol Methyltransferase Inhibitor (\u00b1)-2,3-Dichloro-\u03b1-Methylbenzylamine (DCMB) on the pharmacokinetics and metabolism of vicagrel in rats. Drug Metab Dispos. 2024;52:988\u201396.","journal-title":"Drug Metab Dispos"},{"key":"3470_CR29","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"SP Cohen","year":"2021","unstructured":"Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397:2082\u201397. Plants (Basel). 2023; 12:1536.","journal-title":"Lancet"},{"key":"3470_CR30","unstructured":"Silvano Arruda H, Tecchio Borsoi F, Cristina Andrade A, Maria Pastore G and Marostica Junior MR Scientific Advances in the Last Decade on the Recovery, Characterization, and Functionality of Bioactive Compounds from the Araticum Fruit (Annona crassiflora Mart.)."},{"key":"3470_CR31","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2017.16725","volume":"318","author":"DN Kyriacou","year":"2017","unstructured":"Kyriacou DN. Opioid vs nonopioid acute pain management in the emergency department. JAMA. 2017;318:1655\u20136.","journal-title":"JAMA"},{"key":"3470_CR32","first-page":"704","volume":"78","author":"C Bonezzi","year":"2012","unstructured":"Bonezzi C, Demartini L, Buonocore M. Chronic pain: not only a matter of time. Minerva Anestesiol. 2012;78:704\u201311.","journal-title":"Minerva Anestesiol"},{"key":"3470_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","volume":"129","author":"RR Ji","year":"2018","unstructured":"Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129:343\u201366.","journal-title":"Anesthesiology"},{"key":"3470_CR34","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1021\/acs.jcim.5c00078","volume":"65","author":"AAS Gomes","year":"2025","unstructured":"Gomes AAS, Giraldo J. Structural determinants of buprenorphine partial agonism at the \u03bc-Opioid receptor. J Chem Inf Model. 2025;65:5071\u201385.","journal-title":"J Chem Inf Model"},{"key":"3470_CR35","doi-asserted-by":"publisher","first-page":"176333","DOI":"10.1016\/j.ejphar.2024.176333","volume":"966","author":"J Xia","year":"2024","unstructured":"Xia J, Li XY, Zhu HY, Zhou XH, Chen J, Li QH, et al. The \u03bc-opioid receptor-mediated Gi\/o protein and \u03b2-arrestin2 signaling pathways both contribute to morphine-induced side effects. Eur J Pharmacol. 2024;966:176333.","journal-title":"Eur J Pharmacol"},{"key":"3470_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/B978-0-12-801284-0.00006-3","volume":"118","author":"JHW Jacobsen","year":"2014","unstructured":"Jacobsen JHW, Watkins LR, Hutchinson MR. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. Int Rev Neurobiol. 2014;118:129\u201363.","journal-title":"Int Rev Neurobiol"},{"key":"3470_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04777-1","volume":"21","author":"AA Gurgul","year":"2023","unstructured":"Gurgul AA, Najjar Y, Chee A, An H, Che CT, Park TJ, et al. Phenylpropanoid-enriched broccoli seedling extract can reduce inflammatory markers and pain behavior. J Transl Med. 2023;21:922.","journal-title":"J Transl Med"},{"key":"3470_CR38","doi-asserted-by":"publisher","first-page":"105662","DOI":"10.1016\/j.phrs.2021.105662","volume":"169","author":"G Testa","year":"2021","unstructured":"Testa G, Cattaneo A, Capsoni S. Understanding pain perception through genetic painlessness diseases: The role of NGF and proNGF. Pharmacol Res. 2021;169:105662.","journal-title":"Pharmacol Res"},{"key":"3470_CR39","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","volume":"16","author":"ML Rocco","year":"2018","unstructured":"Rocco ML, Soligo M, Manni LG, Aloe LG. Nerve growth factor: Early studies and recent clinical trials. Curr Neuropharmacol. 2018;16:1455\u201365.","journal-title":"Curr Neuropharmacol"},{"key":"3470_CR40","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1158\/0008-5472.CAN-14-1220","volume":"74","author":"G McCaffrey","year":"2014","unstructured":"McCaffrey G, Thompson ML, Majuta L, Fealk MN, Chartier S, Longo G, et al. NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use. Cancer Res. 2014;74:7014\u201323.","journal-title":"Cancer Res"},{"key":"3470_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-1711-1","volume":"17","author":"HJ Yuan","year":"2020","unstructured":"Yuan HJ, Du SB, Chen LP, Xu XQ, Wang YF, Ji FH. Hypomethylation of nerve growth factor (NGF) promotes binding of C\/EBP\u03b1 and contributes to inflammatory hyperalgesia in rats. J Neuroinflammation. 2020;17:34.","journal-title":"J Neuroinflammation"},{"key":"3470_CR42","doi-asserted-by":"publisher","first-page":"e183873","DOI":"10.1172\/JCI183873","volume":"135","author":"CJ Peach","year":"2024","unstructured":"Peach CJ, Tonello R, Damo E, Gomez K, Calderon-Rivera A, Bruni R, et al. Neuropilin-1 inhibition suppresses nerve growth factor signaling and nociception in pain models. J Clin Invest. 2024;135:e183873.","journal-title":"J Clin Invest"},{"key":"3470_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41582-020-00415-2","volume":"16","author":"M Alsaloum","year":"2020","unstructured":"Alsaloum M, Higerd GP, Effraim PR, Waxman SG. Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat Rev Neurol. 2020;16:689\u2013705.","journal-title":"Nat Rev Neurol"},{"key":"3470_CR44","doi-asserted-by":"publisher","first-page":"102538","DOI":"10.1016\/j.cbpa.2024.102538","volume":"83","author":"H Wang","year":"2024","unstructured":"Wang H, Huang J, Zang J, Jin XQ, Yan N. Drug discovery targeting Nav1.8: Structural insights and therapeutic potential. Curr Opin Chem Biol. 2024;83:102538.","journal-title":"Curr Opin Chem Biol"},{"key":"3470_CR45","doi-asserted-by":"publisher","first-page":"101338","DOI":"10.1016\/j.xcrm.2023.101338","volume":"4","author":"YZ Li","year":"2023","unstructured":"Li YZ, Ge X, Ji RR. Pain management by chemogenetic control of sensory neurons. Cell Rep Med. 2023;4:101338.","journal-title":"Cell Rep Med"},{"key":"3470_CR46","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, Strooper BD, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"3470_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sodium oligomannate: First approval. Drugs. 2020;80:441\u20134.","journal-title":"Drugs"},{"key":"3470_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2020.04.008","volume":"41","author":"O Benek","year":"2020","unstructured":"Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimer\u2019s disease. Trends Pharmacol Sci. 2020;41:434\u201345.","journal-title":"Trends Pharmacol Sci"},{"key":"3470_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07971-8","volume":"10","author":"JC Sun","year":"2019","unstructured":"Sun JC, Carlson-Stevermer J, Das U, Shen MJ, Delenclos M, Snead AM, et al. CRISPR\/Cas9 editing of APP C-terminus attenuates \u03b2-cleavage and promotes \u03b1-cleavage. Nat Commun. 2019;10:53.","journal-title":"Nat Commun"},{"key":"3470_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, AL-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464\u201388.","journal-title":"Mol Ther"},{"key":"3470_CR51","doi-asserted-by":"publisher","first-page":"103691","DOI":"10.1016\/j.ebiom.2021.103691","volume":"74","author":"W Grabowska-Pyrzewicza","year":"2021","unstructured":"Grabowska-Pyrzewicza W, Wanta A, Leszek J, Wojdaa U. Antisense oligonucleotides for Alzheimer\u2019s disease therapy: From the Mrna to miRNA paradigm. EBioMedicine. 2021;74:103691.","journal-title":"EBioMedicine"},{"key":"3470_CR52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jalz.2012.05.2115","volume":"8","author":"LM Refolo","year":"2012","unstructured":"Refolo LM, Snyder H, Liggins C, Ryan L, Silverberg N, Petanceska S, et al. Common Alzheimer\u2019s disease research ontology: National institute on aging and Alzheimer\u2019s Association collaborative project. Alzheimers Dement. 2012;8:372\u20135.","journal-title":"Alzheimers Dement"},{"key":"3470_CR53","doi-asserted-by":"publisher","first-page":"e70098","DOI":"10.1002\/trc2.70098","volume":"11","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Zhou YD, Lee G, Zhong K, Fonseca J, Leisgang-Osse AM, et al. Alzheimer\u2019s disease drug development pipeline: 2025. Alzheimers Dement (N Y). 2025;11:e70098.","journal-title":"Alzheimers Dement (N Y)"},{"key":"3470_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-018-0299-8","volume":"13","author":"JQ Cao","year":"2018","unstructured":"Cao JQ, Hou JW, Ping J, Cai DM. Advances in developing novel therapeutic strategies for Alzheimer\u2019s disease. Mol Neurodegener. 2018;13:64.","journal-title":"Mol Neurodegener"},{"key":"3470_CR55","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2020.4478","volume":"78","author":"ES Musiek","year":"2021","unstructured":"Musiek ES, Morris JC. Possible consequences of the approval of a disease-modifying therapy for Alzheimer disease. JAMA Neurol. 2021;78:141\u20132.","journal-title":"JAMA Neurol"},{"key":"3470_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHV Dyck","year":"2023","unstructured":"Dyck CHV, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"3470_CR57","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","volume":"84","author":"C Kang","year":"2024","unstructured":"Kang C. Donanemab: First approval. Drugs. 2024;84:1313\u20138.","journal-title":"Drugs"},{"key":"3470_CR58","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13195-024-01584-8","volume":"16","author":"YR Yang","year":"2024","unstructured":"Yang YR, Qiu HY, Fan YR, Zhang Q, Qin HL, Wu J, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single intravenous dose of SHR-1707 in healthy adult subjects: two randomized, double-blind, single-ascending-dose, phase 1 studies. Alzheimers Res Ther. 2024;16:218.","journal-title":"Alzheimers Res Ther"},{"key":"3470_CR59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, Day CM, Abdella S, Sanjay Garg S. Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024;367:402\u201324.","journal-title":"J Control Release"},{"key":"3470_CR60","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ageing\/afx045","volume":"46","author":"SF Xiao","year":"2017","unstructured":"Xiao SF, Wang T, Ma XQ, Qin YY, Li X, Zhao ZX, et al. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer\u2019s disease: a Phase II multicenter randomised controlled trial. Age Ageing. 2017;46:767\u201373.","journal-title":"Age Ageing"},{"key":"3470_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Katherine","year":"2022","unstructured":"Katherine KO, Glotfelty EJ, Li YZ, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res. 2022;186:106550.","journal-title":"Pharmacol Res"},{"key":"3470_CR62","unstructured":"World Health Organization. Depressive Disorder (Depression). World Health Organization (2023). Available online at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression."},{"key":"3470_CR63","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/ijerph20032385","volume":"20","author":"YY Ren","year":"2023","unstructured":"Ren YY, Yu J, Zhang G, Zhang C, Liao WM. The short- and long-run impacts of air pollution on human health: New evidence from China. Int J Environ Res Public Health. 2023;20:2385.","journal-title":"Int J Environ Res Public Health"},{"key":"3470_CR64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00213-014-3688-x","volume":"232","author":"M Zheng","year":"2015","unstructured":"Zheng M, Appel L, Luo F, Lane R, Burt D, Risinger R, et al. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. Psychopharmacology. 2015;232:529\u201340.","journal-title":"Psychopharmacology"},{"key":"3470_CR65","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/JCP.0000000000000335","volume":"35","author":"Z Bhagwagar","year":"2015","unstructured":"Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, et al. Assessment of the efficacy and safety of BMS-820836 in patients with treatment-resistant major depression. J Clin Psychopharmacol. 2015;35:454\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"3470_CR66","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biopsych.2021.05.008","volume":"90","author":"E Castr\u00e9n","year":"2021","unstructured":"Castr\u00e9n E, Monteggia LM. Brain-Derived neurotrophic factor signaling in depression and antidepressant action. Biol Psychiatry. 2021;90:128\u201336.","journal-title":"Biol Psychiatry"},{"key":"3470_CR67","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.3390\/ijerph20085570","volume":"20","author":"S Jagan","year":"2023","unstructured":"Jagan S, Mohd Daud TI, Chia LC, Saini SM, Midin M, Eng-Teng N, et al. Evidence for the effectiveness of psychological interventions for internalized stigma among adults with schizophrenia spectrum disorders: A systematic review and meta-analyses. Int J Environ Res Public Health. 2023;20:5570.","journal-title":"Int J Environ Res Public Health"},{"key":"3470_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.848472","volume":"13","author":"K Guo","year":"2022","unstructured":"Guo K, Feng Z, Chen S, Yan ZQ, Jiao ZM, Feng D. Safety profile of antipsychotic drugs: Analysis based on a provincial spontaneous reporting systems database. Front Pharmacol. 2022;13:848472.","journal-title":"Front Pharmacol"},{"key":"3470_CR69","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1124\/pharmrev.121.000540","volume":"74","author":"DJ Luessen","year":"2022","unstructured":"Luessen DJ, Conn PJ. Allosteric modulators of metabotropic glutamate receptors as novel therapeutics for neuropsychiatric disease. Pharmacol Rev. 2022;74:630\u201361.","journal-title":"Pharmacol Rev"},{"key":"3470_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000477313","volume":"86","author":"G Chouinard","year":"2017","unstructured":"Chouinard G, Samaha AN, Chouinard VA, Peretti CS, Kanahara N, Takase M, et al. Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86:189\u2013219.","journal-title":"Psychother Psychosom"},{"key":"3470_CR71","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","volume":"66","author":"BJ Kinon","year":"2013","unstructured":"Kinon BJ, G\u00f3mez JC. Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2013;66:82\u20136.","journal-title":"Neuropharmacology"},{"key":"3470_CR72","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar RS, Breier A, Zhu HY, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. The Lancet. 2024;403:160\u201370.","journal-title":"The Lancet"},{"key":"3470_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108275","volume":"239","author":"SH Li","year":"2022","unstructured":"Li SH, Abd-Elrahman KS, Ferguson SSG. Targeting mGluR2\/3 for treatment of neurodegenerative and neuropsychiatric diseases. Pharmacol Ther. 2022;239:108275.","journal-title":"Pharmacol Ther"},{"key":"3470_CR74","doi-asserted-by":"publisher","first-page":"ITC33","DOI":"10.7326\/AITC202103160","volume":"174","author":"BMN Perez","year":"2021","unstructured":"Perez BMN, Salas RME. Insomnia. Ann Intern Med. 2021;174:ITC33\u2013ITC48.","journal-title":"Ann Intern Med"},{"key":"3470_CR75","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000506868","volume":"89","author":"F Cosci","year":"2020","unstructured":"Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89:283\u2013306.","journal-title":"Psychother Psychosom"},{"key":"3470_CR76","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/CON.0000000000001283","volume":"29","author":"BS Kutscher","year":"2023","unstructured":"Kutscher BS, Christine Juang C. Insomnia. Continuum (Minneap Minn). 2023;29:1167\u201387.","journal-title":"Continuum (Minneap Minn)"},{"key":"3470_CR77","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.2147\/DDDT.S501111","volume":"19","author":"J Ni","year":"2025","unstructured":"Ni J, Jin L, Zhao D, Zhang W, Li BS, Huang XX, et al. Pharmacokinetics, pharmacodynamic, safety and tolerability of fazamorexant, a novel dual orexin receptor antagonist: Report of the first-in-human study. Drug Des Devel Ther. 2025;19:5271\u201382.","journal-title":"Drug Des Devel Ther"},{"key":"3470_CR78","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40265-024-02020-9","volume":"84","author":"YY Syed","year":"2024","unstructured":"Syed YY. Dimdazenil: First approval. Drugs. 2024;84:607\u201311.","journal-title":"Drugs"},{"key":"3470_CR79","volume":"6","author":"DC Zhai","year":"2025","unstructured":"Zhai DC, Zhang QY, Lu XL, You QD, Wang L. Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights. Innovation (Camb). 2025;6:100801.","journal-title":"Innovation (Camb)"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03470-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03470-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03470-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:04:12Z","timestamp":1779282252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03470-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3470"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03470-1","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Xiangqing Xu is an employee for Jiangsu Nhwa Pharmaceutical Co., Ltd. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}